Data Insights

2025 saw some shakeups to the sales rankings of big pharma, but with widespread major asset patent losses, 2026 and beyond could prove even more turbulent.

The biopharma sector announced 41 merger-and-acquisition deals during Q1 2026, according to Evaluate, with a late March run of multibillion-dollar bids.